Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nimodipine microparticles - PDS Biotechnology Corporation

Next Previous
Drug Profile

Nimodipine microparticles - PDS Biotechnology Corporation

Alternative Names: EG-1962; NimoVent; Polymeric nimodipine microparticle

Latest Information Update: 25 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Edge Therapeutics
  • Developer PDS Biotechnology Corporation
  • Class Antihaemorrhagics; Antihypertensives; Dihydropyridines; Esters; Nicotinic acids; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Subarachnoid haemorrhage
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cerebral ischaemia

Most Recent Events

  • 18 Mar 2019 PDS Biotechnology Corporation merged with Edge Therapeutics to form PDS Biotechnology Corporation
  • 27 Jun 2018 Efficacy data from a phase III NEWTON 2 trial in Cerebral ischaemia released by Edge Therapeutics
  • 04 Apr 2018 Edge Therapeutics terminates a phase I trial in Cerebral ischaemia (Prevention) in USA (Intracisternal) (NCT02893826)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top